Display of Biologics

Phage, yeast, and mammalian display are essential tools for creating the vast arsenal of emerging biologic constructs, including multispecifics, ADCs, and immunotherapies. The integration of ML/AI to assess developability and enable optimization of candidates, along with computational modeling, have led to new workflows in the discovery engine. New methods of conditional activation and masking strategies allow biologics to hit the tumor before they become activated, reducing off-target toxicity and adverse events. Cambridge Healthtech Institute's Twelfth Annual Display of Biologics conference is the cornerstone of the PEGS Europe Summit, and will assemble pioneers advancing new classes of therapy.

Scientific Advisory Board
Maria Groves, PhD, Senior Director, AstraZeneca
Geir Åge Løset, PhD, CEO and CSO, Nextera AS
Ahuva Nissim, PhD, Professor Emeritus, Antibody and Therapeutic Engineering, William Harvey Research Institute, Queen Mary University of London
E. Sally Ward, PhD, Director, Translational Immunology; Professor, Molecular Immunology, Centre for Cancer Immunology, University of Southampton